These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 17973316)

  • 21. [Relapse of biphenotypic leukemia confirmed by molecular study].
    Onozawa M; Hashino S; Izumiyama K; Yonezumi M; Chiba K; Kondo T; Tanaka J; Imamura M; Asaka M
    Rinsho Ketsueki; 2004 Feb; 45(2):161-3. PubMed ID: 15045826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?
    Buser A; Stern M; Arber C; Medinger M; Halter J; Rovo A; Favre G; Lohri A; Tichelli A; Gratwohl A
    Bone Marrow Transplant; 2008 Oct; 42(7):483-7. PubMed ID: 18695668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel antibody-based therapy for acute lymphoblastic leukaemia.
    Gökbuget N; Hoelzer D
    Best Pract Res Clin Haematol; 2006; 19(4):701-13. PubMed ID: 16997178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation by RQ-PCR and flow cytometry of alpha-defensin1-3 (DEFA1-3) overexpression in relapsed and refractory acute lymphoblastic leukemia.
    Te Kronnie G; Bicciato S; Franceschini L; Accordi B; Dellíorto MC; Rinaldi A; Pession A; Barisone E; Conter V; Locatelli F; Basso G
    Oncol Rep; 2006 Feb; 15(2):341-6. PubMed ID: 16391852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring minimal residual disease with flow cytometry, antigen-receptor gene rearrangements and fusion transcript quantification in Philadelphia-positive childhood acute lymphoblastic leukemia.
    Thörn I; Botling J; Hermansson M; Lönnerholm G; Sundström C; Rosenquist R; Barbany G
    Leuk Res; 2009 Aug; 33(8):1047-54. PubMed ID: 19157547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Fuster JL; Bermúdez M; Galera A; Llinares ME; Calle D; Ortuño FJ
    Haematologica; 2007 Dec; 92(12):1723-4. PubMed ID: 18056006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatal course after administration of rituximab in a boy with relapsed all: a case report and review of literature.
    Seifert G; Reindl T; Lobitz S; Seeger K; Henze G
    Haematologica; 2006 Jun; 91(6 Suppl):ECR23. PubMed ID: 16785126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
    Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
    Lönnerholm G; Thörn I; Sundström C; Frost BM; Abrahamsson J; Behrendtz M; Heldrup J; Jacobsson S; Li A; Olofsson T; Porwit A; Söderhäll S; Larsson R; Forestier E
    Leuk Res; 2009 Jan; 33(1):46-53. PubMed ID: 18639340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.
    Ryan J; Quinn F; Meunier A; Boublikova L; Crampe M; Tewari P; O'Marcaigh A; Stallings R; Neat M; O'Meara A; Breatnach F; McCann S; Browne P; Smith O; Lawler M
    Br J Haematol; 2009 Jan; 144(1):107-15. PubMed ID: 19016726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL.
    Gudowius S; Recker K; Laws HJ; Dirksen U; Tröger A; Wieczorek U; Furlan S; Göbel U; Hanenberg H
    Klin Padiatr; 2006; 218(6):327-33. PubMed ID: 17080335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
    von Stackelberg A; Seeger K; Henze G; Eckert C
    Leukemia; 2004 Oct; 18(10):1727-8; author reply 1728-9. PubMed ID: 15356653
    [No Abstract]   [Full Text] [Related]  

  • 35. Clonal stability of initial leukemia in a child with central nervous system relapse 7.4 years after bone marrow relapse of common acute lymphoblastic leukemic.
    Eckert C; Einsiedel HG; Hartmann R; von Stackelberg A; Völpel S; Guggemos A; Hanzsch N; Kawan L; Seeger K; Henze G
    Haematologica; 2004 Jul; 89(7):ECR23. PubMed ID: 15257960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
    DiGiuseppe JA; Fuller SG; Borowitz MJ
    Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
    Ratanatharathorn V; Pavletic S; Uberti JP
    Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
    Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: a study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon).
    Muñoz A; Diaz-Heredia C; Diaz MA; Badell I; Verdeguer A; Martinez A; Gomez P; Perez-Hurtado JM; Bureo E; Fernandez-Delgado R; Gonzalez-Valentin ME; Maldonado MS
    Pediatr Hematol Oncol; 2008 Jun; 25(4):245-59. PubMed ID: 18484470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Limited but potential efficacy by graft-versus-leukemia (GVL) for Pro T-ALL].
    Imataki O; Koike A; Iwabu M; Shintani T; Waki F; Ohue Y; Ohnishi H; Ishida T
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1911-4. PubMed ID: 19011341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.